Key Takeaways
Newlimit raised a $435 million Collection C led by Founders Fund, introduced June 2.The spherical lifted the biotech’s valuation to about $3.1 billion, roughly triple its prior mark.Newlimit plans to deliver its first cell-aging reprogramming medication into human trials subsequent yr.
Crypto Wealth Flows Into Longevity Science
Newlimit, the anti-aging biotech co-founded by Coinbase International Inc. (Nasdaq: COIN) Chief Government Brian Armstrong, has closed a $435 million Collection C funding spherical, the corporate introduced on June 2. The elevate was led by Founders Fund and roughly tripled Newlimit’s post-money valuation to about $3.1 billion, up from a mark that sat beneath $1 billion at its earlier spherical.
The financing drew a roster of high-profile backers, together with new traders like Thrive Capital, Greenoaks, and Quiet Capital. Returning supporters included Kleiner Perkins, Summary, and Valor Fairness Companions, every of whom added to their present stakes.
Based in 2021 by Armstrong, former GV associate and bioengineer Blake Byers, and stem cell biologist Mark Kimmel, Newlimit is constructed on a single thesis, i.e. growing older is “plastic,” or reversible, on the mobile degree. The corporate develops medicines designed to revive youthful perform to previous cells by means of epigenetic reprogramming, a method that goals to reset how genes are expressed with out altering the underlying DNA.
From a Facet Venture to a $3 Billion Wager
Newlimit has grown rapidly and the numbers spell that fairly clearly. The startup raised $130 million as not too long ago as final yr, which means the brand new spherical greater than triples its valuation in roughly twelve months. The corporate has mentioned the accelerated timeline was pushed by a prototype medication breakthrough that reverses cell age in previous human liver cells, giving the staff confidence to push towards the clinic.
That progress units up the corporate’s most essential milestone but, as Newlimit mentioned it plans to deliver its first aging-reprogramming medication into human scientific trials subsequent yr, a step that may transfer the agency from laboratory analysis into regulated drug growth.
Furthermore, epigenetic reprogramming, the science underpinning Newlimit, has turn out to be probably the most intently watched and closely funded areas of biotechnology. The method builds on Nobel-winning analysis exhibiting that mature cells could be coaxed again towards a youthful state, and a wave of startups has raced to show that perception into therapies. Newlimit’s newest elevate locations it among the many best-capitalized names within the discipline.
Armstrong’s Increasing Footprint
For Armstrong, the spherical highlights a portfolio that now stretches effectively past Coinbase. He has used his crypto fortune to again bold science and infrastructure initiatives, framing longevity as one of many defining technological challenges of the period. Bitcoin.com Information has reported on Armstrong’s operating commentary about modernizing finance and the broader onchain economic system, and his biotech wager runs on a parallel monitor of long-horizon, high-risk investing.
The Founders Fund-led spherical additionally displays renewed investor urge for food for moonshot biotech at a time when crypto markets have been wobbling. Backers are betting that breakthroughs in mobile reprogramming might finally produce remedies for age-related illness, a market measured within the trillions if the science delivers.
The subsequent take a look at is the clinic and Newlimit’s transfer into human trials subsequent yr would be the first real-world learn on whether or not its laboratory outcomes translate into protected, efficient medicines.
